Definium Therapeutics

For the millions of adults living with major depressive disorder (MDD), misperceptions about the condition compound its burden. MDD is a complex mental disorder that often includes feelings of worthlessness, fatigue, and impaired social functioning. We are working toward developing treatments that target the underlying causes of psychiatric and neurological disorders to provide potential relief that goes beyond “better." Learn more about our progress here: definiumtx.com/clinical-trial… #HealthcareInnovation #Neuroscience #DefiniumTherapeutics #MentalHealth #MDD #RaiseTheBar #WeCanDoBetter

Today marks the anniversary of the @988Lifeline. Since 2022, the 988 Suicide and Crisis line has answered over 13 million calls, texts and chats. Progress and support like this in mental health care is pivotal. We will not waiver from our commitment to raising awareness and advancing the science behind potential new mental health treatments for all. For more details about the 988 hotline, click here: 988lifeline.org/about/ #HealthcareInnovation #Neuroscience #DefiniumTherapeutics #MentalHealth

Here’s a harsh reality mental health professionals know all too well. Many people living with generalized anxiety disorder (GAD) experience constant, overwhelming worry with no sustained relief. The fact is, patients living with GAD deserve more than better.   Now for some good news. Countless researchers have worked tirelessly to uncover a deeper understanding of the neurobiology behind GAD, revealing how dysregulated activity and connectivity in the prefrontal cortex, amygdala, and thalamus may contribute to negative thinking patterns and worry. Understanding the disease better can help deliver more than better for patients.    Check out “Wired for Worry,” a new HCP educational initiative designed to support the urgent need to more deeply understand GAD’s symptoms, lifelong effects on patients, and the underlying neurobiology.   Learn more here: bit.ly/44yYbRn   #GAD #WiredforWorry #HealthcareInnovation #Neuroscience #DefiniumTherapeutics #MentalHealth

Forging a future in psychiatry where mental healthcare is accessible means confronting the disparities that leave too many people behind. During BIPOC Mental Health Awareness Month, also known as Bebe Moore Campbell National Minority Mental Health Awareness Month, we join organizations like the National Alliance on Mental Health (@NAMICommunicate) to acknowledge the significance of this month and the fact that there is still work to do. Together, we’re focusing on dismantling the misperceptions around mental health disorders and relentlessly pursuing potential new treatments for those who need it most. See resources and information here: nami.org/stay-connected…  #BIPOCMentalHealthMonth #HealthcareInnovation #Neuroscience #DefiniumTherapeutics #MentalHealth #SeenHeardUnderstood #MinorityMentalHealth

Independence Day is a reminder of the sacrifices and deep commitment veterans have made to protect the US. Millions of veterans experience posttraumatic stress disorder (PTSD), and they deserve more options to support their mental health after they return home from service. We are driven by this need and continue to progress research in pharmaceutical LSD as a potential treatment option. Together, we can better support the veteran community to address unmet needs in mental health care. Learn more: definiumtx.com/pipeline/dt120/ #PTSDAwareness #IndependenceDay #HealthcareInnovation #Neuroscience #DefiniumTherapeutics #MentalHealth

Posttraumatic stress disorder (PTSD) is a deeply complex, often overlooked, and widely under researched condition – and we’re not shying away from it. Roughly 6% of Americans will experience PTSD at some point in their lives, with veterans and women more likely to develop it. Awareness of PTSD has grown, but those who live with it still deserve better care and better treatment options. Next year will mark the start of our Phase 3 Haven study to explore novel treatments for PTSD. For the millions suffering with the disorder, we hope this commitment brings hope. To learn more about PTSD Awareness Month, please visit: ptsd.va.gov/understand/awa… #PTSD #MentalHealth #Neuroscience #HealthcareInnovation #DefiniumTherapeutics

The positive topline results from our Phase 3 Emerge clinical trial represent more than a company milestone, they reflect growing momentum toward potential new treatment possibilities for people living with major depressive disorder (MDD). Hear from Emerge Principal Investigator and practicing clinical psychologist, John Sonnenberg, Ph.D., who shares his perspective on the significance of these findings and how the growing body of evidence surrounding psychedelics like pharmaceutical LSD is fueling excitement and optimism across the field of psychiatry. Check out our recent press release to learn more about the Emerge Phase 3 topline data: bit.ly/4xXCOqu #MentalHealth #DefiniumTherapeutics #Psychedelics #HealthcareInnovation #MDD #Depression

Milestone unlocked 🔓🔑. Today, we announced positive topline results from Emerge, the first Phase 3 study of our pharmaceutical LSD for major depressive disorder (MDD). These results mark a significant step forward in our mission to forge a new era of psychiatry, one with novel treatments that target underlying cause of disease, not just symptoms. For patients who may have run out of options, these results matter. We’re energized by the momentum ahead as we continue pursuing potential new treatment options for the millions of people living with a mental health disorder. Learn more about this significant step: bit.ly/4xXCOqu

#Sponsored At Definium, we’re advancing a deeper understanding of mental health through rigorous science and innovation. Hear from Rakesh Jain, MD, MPH, on why neuroplasticity is important as we continue our efforts to better understand and address mental health disorders. Learn more about how we’re Rerouting Minds here: bit.ly/4qqoLVo #MentalHealthInnovation #DefiniumTheraputics #Biotech

#Sponsored The "psychedelic renaissance" is here. Rakesh Jain, MD, MPH, discusses the potential of pharmaceutical LSD for mental healthcare. Learn more: bit.ly/49HJOME #ReroutingMinds

#Sponsored  Neuroplasticity & psychedelics: Can they break negative cycles? Rakesh Jain, MD, MPH, explores the concept of neuroplasticity – the brain's ability to adapt. Learn more: bit.ly/49HJOME  #ReroutingMinds

Last week at the @ASCPorg Annual Meeting, our CMO @dankarlin and Med Affairs Executive Director @jessicam828 had the opportunity to sit down with Psychiatric Times to discuss comprehensive data regarding DT120 ODT. Watch the video here: psychiatrictimes.com/view/dt-120-fo… #MentalHealth #HealthcareInnovation #DefiniumTherapeutics #Psychedelics

We look forward to attending the Jefferies Healthcare Conference this Wednesday, June 3. Our CEO, @Robertbbarrow, CMO,@dankarlin, and CFO, Brandi Roberts, will be participating in a fireside chat at 3:10 PM EDT. If you’re attending, we encourage you to listen in on this discussion outlining our strategy for advancing a potential new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders. Check out the press release for additional details: ir.definiumtx.com/news-events/pr… #Jefferies2026 #MentalHealth #Neuroscience #HealthcareInnovation #DefiniumTherapeutics

Reporting live from the @ASCPorg Annual Meeting in Miami Beach, where the future of mental health care is taking center stage! The Definium team joined industry leaders to discuss how Artificial Intelligence (AI) is shaping psychiatric drug development. Chief Medical Officer, @dankarlin, and Senior Director of Clinical Development, Todd M. Solomon, PhD, participated in a panel on AI and Large Language Models (LLMs) in psychiatry. Thank you to all the conference organizers and attendees for an inspiring week of collaboration and innovation. #MentalHealth #HealthcareInnovation #DefiniumTherapeutics #Psychedelics

This #MentalHealthAwarenessMonth, we join @NAMICommunicate's effort to "Turn silence into connection" and @MentalHealthAm's goal to create "More good days, together." These themes deeply resonate with our mission to forge a new era of psychiatry by harnessing the full therapeutic potential of psychedelic medicine. We believe that by fostering connection and breaking the silence around mental health, we can collectively work towards a future where more individuals experience brighter, healthier days. #MHAM #MentalHealthAwareness #NAMI #MHA

The Definium team is back in New York! We look forward to attending the Jefferies Global Healthcare Conference to continue the conversation around Definium's efforts to develop a new generation of therapeutics to address underlying causes of psychiatric and neurological disorders. If you're attending, join in on a fireside chat on June 3rd at 3:10 p.m. EDT as part of this discussion. Read the press release for additional details: ir.definiumtx.com/news-events/pr… #Jefferies2026 #MentalHealth #Neuroscience #HealthcareInnovation #DefiniumTherapeutics